Marchetti P, Sabino F, Giannarelli R, DiCarlo A, Cicchetti V, Navalesi R
Zambon Group, Corporate Medical Department, Bresso-Milano, Italy.
Cardiology. 1990;77 Suppl 5:57-62. doi: 10.1159/000174697.
Twelve outpatients with type II diabetes mellitus and mild clinical signs and history of cardiac failure were studied to assess the effects of ibopamine on glucose and lipid metabolism. For the assessment of cardiac failure a clinical score was computed, based on the evidence of dyspnea and ankle oedema. The patients were randomly allocated to ibopamine 100 mg t.i.d. or placebo in a double-blind cross-over 3 weeks design. Daily plasma glucose profile, glycaemia and plasma insulin during glucose tolerance test, serum C-peptide, lactacidemia, free fatty acids, triglycerides, urinary glucose, diuresis and clinical evaluation were the studied parameters. During the study, a clinically favourable trend for ibopamine was observed, as far as cardiac failure was concerned. No significant differences were found between ibopamine and placebo in any of the metabolic parameters. No change in diet or in the previous dosage of the antidiabetic drugs occurred during the study in any patient. We conclude that ibopamine 100 mg t.i.d. does not affect metabolic control and lipid pattern in type II diabetic patients, therefore representing a safe tool for the treatment of chronic heart failure in these patients.
对12名患有II型糖尿病且有轻度临床症状和心力衰竭病史的门诊患者进行了研究，以评估异波帕明对糖脂代谢的影响。为评估心力衰竭，根据呼吸困难和脚踝水肿情况计算临床评分。患者被随机分配接受每日三次、每次100毫克的异波帕明或安慰剂治疗，采用双盲交叉3周设计。研究参数包括每日血糖谱、葡萄糖耐量试验期间的血糖和血浆胰岛素、血清C肽、乳酸血症、游离脂肪酸、甘油三酯、尿糖、尿量以及临床评估。在研究期间，就心力衰竭而言，观察到异波帕明有临床有利趋势。在任何代谢参数方面，异波帕明与安慰剂之间均未发现显著差异。在研究期间，任何患者的饮食或先前抗糖尿病药物的剂量均未改变。我们得出结论，每日三次、每次100毫克的异波帕明不会影响II型糖尿病患者的代谢控制和血脂模式，因此是治疗这些患者慢性心力衰竭的安全药物。
